Table 1 Clinical characteristics of Behcet’s disease (BD) and healthy controls (HC)
From: Identification of the immune-related biomarkers in Behcet’s disease by plasma proteomic analysis
Overall | Female | Male | p. value | |
|---|---|---|---|---|
HC | ||||
HC (N, %) | 25 | 12 (48.00) | 13 (52.00) | |
Age (mean (SD)) | 40.28 (8.11) | 41.67 (8.54) | 39.00 (7.81) | 0.423 |
BD | ||||
BD (N, %) | 27 | 13 (48.10) | 14 (51.90) | |
Age (mean (SD)) | 33.37 (14.19) | 36.92 (17.70) | 30.07 (9.44) | 0.216 |
Treatment (%) | 8 (29.60) | 2 (15.40) | 6 (42.90) | 0.322 |
Disease duration (months) (median (Q1, Q3)) | 36.00 (21.50–74.00) | 36.00 (24.00–40.00) | 68.50 (20.25–75.00) | 0.593 |
Oral or Genital ulcers (%) | 27 (100.00) | 13 (100.00) | 14 (100.00) | |
Skin involvement (%) | 8 (29.60) | 4 (30.80) | 4 (28.60) | 1.000 |
Joint involvement (%) | 7 (25.90) | 4 (30.80) | 3 (21.40) | 0.909 |
Uveitis (%) | 14 (51.90) | 7 (53.80) | 7 (50.00) | 1.000 |
Vascular involvement (%) | 4 (14.80) | 0 (0.00) | 4 (28.60) | 0.122 |
Neurological involvement (%) | 2 (7.40) | 2 (15.40) | 0 (0.00) | 0.430 |
Gastrointestinal involvement (%) | 2 (7.40) | 1 (7.70) | 1 (7.10) | 1.000 |